Comparison · NCT00628628-cc2a3a22
Group A: Single Dose vs Group B: Daily Dose: Number of Participants With Plasma Uric Acid (UA) Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A: Single Dose vs Group B: Daily Dose: Number of Participants With Plasma Uric Acid (UA) Response. Trial comparisons, record NCT00628628-cc2a3a22. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00628628-cc2a3a22
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.975 | 0.871 | 0.996 | wilson | |
| Risk in group 2 | 0.85 | 0.709 | 0.929 | wilson | |
| Risk difference, group 1 minus group 2 | 0.125 | -0.00569 | 0.267 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.15 | 0.998 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 6.88 | 0.789 | 60.1 | log | |
| Number needed to treat, for one more participant with the outcome on Group A: Single Dose than on Group B: Daily Dose | 8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A: Single Dose | As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed. | 39 | 40 | OG000 |
| Group 2 | Group B: Daily Dose | Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily | 34 | 40 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Plasma Uric Acid (UA) Response
- Description
Plasma UA response is defined as normalization of plasma UA levels within 48 hours after the start of study drug (rasburicase) and maintaining within the normal range after the final drug infusion on day 5. Plasma samples for UA were collected at baseline before rasburicase, 4- and 24-hours post-rasburicase, and daily during treatment.
- Time frame
- First cycle of chemotherapy, up to 5 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Rasburicase in Patients at Risk for Tumor Lysis Syndrome
- NCT number
- NCT00628628
- Phases
- PHASE2
- Conditions
- Tumor Lysis Syndrome
- Interventions
- As Needed Rasburicase, Fixed Dose Rasburicase
- Lead sponsor
- M.D. Anderson Cancer Center
- Results first posted
- 2013-08-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00628628?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00628628-cc2a3a22